Assessment of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker on the split renal function in the patients with primary hypertension

被引:1
|
作者
Zhang, Jingsi [1 ]
Wang, Mingyu [1 ]
Sun, Kehui [1 ]
Ding, Yanchun [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dept Cardiol 2, Dalian, Peoples R China
关键词
ACEI; ARB; primary hypertension; renal dynamic imaging; split renal function; KIDNEY-DISEASE; BLOOD-PRESSURE; IRBESARTAN; MORTALITY;
D O I
10.1097/MD.0000000000025928
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bilateral kidney damage in hypertensive patients is not parallel. Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), as a commonly used antihypertensive drug, could protect kidney function and delay its deterioration. Most studies focused on overall renal function, but the researches on split renal function (SRF) are rare. We investigated the effects of ACEI/ARB on the SRF in patients with primary hypertension. Patients with primary hypertension (n = 429; male: 213; female: 216) admitted to our department between January 2014 and December 2016 were included in this study. The glomerular filtration rate (GFR) of split and total renal function were determined using diethylenetriaminepentaacetic acid tagged with 99mTc renal dynamic imaging method. For the same patient, the side with high GFR was considered as higher GFR kidney, whereas that with a low GFR was considered as lower GFR kidney. The split function score (Q value) was utilized to evaluate the differences of bilateral renal function. The patients were divided into 3 groups based on the Q values (Group 1, Q value <5%; Group 2, Q value of 5%-10%; Group 3, Q value >= 10%). All the patients received antihypertensive therapy based on ACEI/ARB. The renal dynamic imaging was performed in the 1-year follow-up to investigate the changes of the SRF. Compared with the baseline level, significant decline was noticed in the serum creatinine (Scr) in Group 2 and Group 3 (P < .05). The cystatin C in Group 3 showed significant decline (P < .05). Compared with the baseline, there was significant decline in the Q value in Group 2, whereas the GFR of lower GFR kidney showed significant increase (P < .05). No statistical differences were noticed in the Q value and split GFR in Group 1 and Group 3 (P > .05). In primary hypertension patients, ACEI/ARB therapy could improve the SRF of lower GFR kidney in the presence of certain differences between the SRF. As a result, the SRF difference was reduced. In case of Q value in a range of 5% to 10%, ACEI/ARB could improve the renal function effectively. It may be significant for the design of antihypertensive drugs.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
    Zhang, Chao
    Zhong, Jun
    Chen, Wei-Xiang
    Zhang, Xu-Yang
    Li, Yu-Hong
    Zhou, Teng-Yuan
    Zou, Yong-Jie
    Lan, Chuan
    Li, Lan
    Lai, Zhao-Pan
    Feng, Hua
    Hu, Rong
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 355 - 363
  • [2] Paradoxical pressor response with angiotensin-converting enzyme inhibitor and angiotensin receptor blocker
    Sabitha, P.
    Adhikari, Prabha M.
    AUSTRALASIAN MEDICAL JOURNAL, 2011, 4 (07): : 364 - +
  • [3] Effects of combination therapy of an angiotensin-converting enzyme inhibitor and an angiotensin receptor blocker
    Idrizi, A
    Gjata, M
    Barbullushi, M
    Koroshi, A
    Tase, M
    Sadiku, E
    Hoti, K
    JOURNAL OF HYPERTENSION, 2005, 23 : S398 - S398
  • [4] Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use and outcomes in patients with colorectal cancer
    Tuazon, Sherilyn Alvaran
    King, Gantry Teng
    Cruz, Joanna Sta.
    Chae, Young K.
    Koc, Jean B. Ong Klan
    Hegarty, Sarah
    Leighton, John Charles
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] THE ANTIPROTEINURIC EFFECT OF COMBINED ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND ANGIOTENSIN RECEPTOR BLOCKER THERAPY IN PRIMARY GLOMERULONEPHRITIS
    Kaptanogullari, Ozlem Harmankaya
    Ozbahar, Yalcin
    Cecen, Ismail
    Kaptanogullari, Hakan
    NEPHROLOGY, 2005, 10 : A168 - A168
  • [6] Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker adherence in patients with primary versus secondary diagnosis of heart failure
    Brackbill, Marcia L.
    Bashaw-Keaton, Rebecca
    Sytsma, Christine S.
    AMERICAN JOURNAL OF MANAGED CARE, 2007, 13 (10): : 568 - 570
  • [7] Advantages of combination therapy of hypertension with calcium channel blocker and angiotensin-converting enzyme inhibitor in patients with impaired renal function
    Dzhaiani, N. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2014, 10 (02) : 238 - 244
  • [8] Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection
    Hou, Fan Fan
    Zhou, Qiu Gen
    NEPHROLOGY, 2010, 15 : 57 - 60
  • [9] Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease
    Molnar, Miklos Z.
    Kalantar-Zadeh, Kamyar
    Lott, Evan H.
    Lu, Jun Ling
    Malakauskas, Sandra M.
    Ma, Jennie Z.
    Quarles, Darryl L.
    Kovesdy, Csaba P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (07) : 650 - 658
  • [10] Clinical Value of Angiotensin-converting Enzyme Inhibitor and Angiotensin Receptor Blocker in the Patients of Coronary Artery Disease
    Abe, Daisuke
    Sato, Akira
    Misaki, Masako
    Takeyasu, Noriyuki
    Hoshi, Tomoya
    Aonuma, Kazutaka
    CIRCULATION, 2013, 128 (22)